Nasdaq: MENS - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Care Career buys MAS Medical Staffing to expand healthcare workforce platform

China uses water cannon against Philippine vessels for second day near Scarborough Shoal

Energy Action reports A$12.2m FY2026 revenue as higher costs pressure earnings

IBM’s planned acquisition of HRL Laboratories could strengthen its quantum computing roadmap by adding silicon-spin qubit technology and expanding its advanced semiconductor research capabilities. Representative image.

Inside the quantum foundry race behind IBM’s move for HRL Laboratories

Representative image of a biotechnology clinical trial setting, reflecting Jyong Biotech’s Phase II prostate cancer prevention research milestone.

Read More

Pharma Industry News

Jyong Biotech stock surges 26.8% as Phase II prostate cancer trial enrollment milestone boosts investor confidence

Jyong Biotech (NASDAQ: MENS) stock jumped 26.8% after completing enrollment of 700 patients in its Phase II prostate cancer prevention trial MCS-8.

byPallavi Madhiraju

September 20, 2025

web analytics